Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 9/20 | 0.52 |
| ▸ | CTSV | O60911 | 4/20 | 0.52 |
| ▸ | CTSL | P07711 | 4/20 | 0.52 |
| ▸ | CTSK | P43235 | 7/20 | 0.47 |
| ▸ | ACE | P12821 | 2/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6805371 | 0.96 | CTSS (0.54) | CTSSCTSVCTSLCTSKACE | |
| SCHEMBL6804944 | 0.94 | CTSS (0.53) | CTSSCTSVCTSLCTSKROCK2 | |
| SCHEMBL6802332 | 0.91 | CTSS (0.51) | CTSSCTSVCTSLCTSKACE | |
| SCHEMBL6799215 | 0.91 | CTSS (0.49) | CTSSCTSVCTSLCTSKROCK2 | |
| SCHEMBL6797583 | 0.91 | CTSS (0.51) | CTSSCTSVCTSLCTSKROCK2 | |
| SCHEMBL6803432 | 0.91 | CTSS (0.51) | CTSSCTSVCTSLCTSKROCK2 | |
| SCHEMBL6808187 | 0.91 | CTSS (0.51) | CTSSCTSVCTSLCTSKROCK2 | |
| SCHEMBL6798994 | 0.91 | CTSS (0.51) | CTSSCTSVCTSLCTSKROCK2 | |
| SCHEMBL6802929 | 0.89 | CTSS (0.53) | CTSSCTSVCTSLCTSKROCK2 | |
| SCHEMBL6798333 | 0.89 | CTSK (0.60) | CTSSCTSVCTSLCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138250-A1 | Inhibitors of cruzipain and other cysteine proteases | GRUNENTHAL GMBH (DE) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138250-A1 | Inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | CTSS 39/4885CTSV 27/4885CTSL 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.